A clinical stage biopharmaceutical company pioneering the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells are a distinct T cell population that combine durable memory responses with the rapid cytolytic features of natural killer (NK) cells.
Lead Underwriter
Evercore Group L.L.C, William Blair & Company, L.L.C.
Co-Managers
B. Riley Securities, Inc, Robert W. Baird & Co. Incorporated
